Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Informatica: Q4 Earnings Insights

Informatica (NYSE:INFA) reported its Q4 earnings results on Wednesday, February 14, 2024 at 04:05 PM. Here’s what investors…
byBenzinga Insights
February 14, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

Informatica (NYSE:INFA) reported its Q4 earnings results on Wednesday, February 14, 2024 at 04:05 PM.

Here’s what investors need to know about the announcement.

Earnings

Informatica beat estimated earnings by 6.67%, reporting an EPS of $0.32 versus an estimate of $0.3.

Revenue was up $46.40 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.04 which was followed by a 17.85% increase in the share price the next day.

Here’s a look at Informatica’s past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 0.23 0.10 0.16 0.21
EPS Actual 0.27 0.17 0.15 0.24
Revenue Estimate 401.53M 360.06M 358.22M 404.17M
Revenue Actual 408.56M 375.99M 365.43M 398.78M

To track all earnings releases for Informatica visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

cbdMD Reports YoY Dip In Q1 Net Sales, Shrinks Operating Loss, Expands Into Hemp And Mushroom Products Markets

By Jelena Martinovic
February 14, 11:03 AM
Medical cannabis company cbdMD has reported financial results for its first quarter of fiscal 2024. Operating loss improved to $1.1m compared to $4.1m for the same period in the previous year. Gross profit was flat at around $3.5m, while operating expenses were $4.6m, down from $7.6m in the previous year. Total net sales declined to $5.37m from almost $6m in the corresponding prior-year period. Direct-to-consumer net sales represented 82.3% of total net sales, a decrease from 90% in Q1 2023. On 31 December 2023, cbdMD had total working capital of roughly $1.4m compared to approximately $3.4m on 30 September, with cash on hand dropping to roughly $1.5m from $1.8m over the same period. The Charlotte-based company recently struck a securities purchase agreement with five institutional investors to fund the national rollout of its ATRx Labs functional mushroom products, as well as launching the hempMD and ATRx Labs brands.

YCBD